Evidence map›Paper›PMID 35976550›Full record

ArticleMolecular diversity2023

Design, synthesis, graph theoretical analysis and molecular modelling studies of novel substituted quinoline analogues as promising anti-breast cancer agents.

Prachita Gauns Dessai, Shivani Prabhu Dessai, Renuka Dabholkar, Padmashree Pednekar, Sahili Naik, Shivlingrao Mamledesai, Murugananthan Gopal, Parasuraman Pavadai, Banoth Karan Kumar, Sankaranarayanan Murugesan and 3 more

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular diversity, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Prachita Gauns DessaiDepartment of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, 403401, India.
Shivani Prabhu DessaiDepartment of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, 403401, India.
Renuka DabholkarDepartment of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, 403401, India.
Padmashree PednekarDepartment of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, 403401, India.
Sahili NaikDepartment of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, 403401, India.
Shivlingrao MamledesaiDepartment of Pharmaceutical Chemistry, PES's Rajaram & Tarabai Bandekar College of Pharmacy, Farmagudi, Ponda, 403401, India.
Murugananthan GopalDepartment of Pharmacognosy, Swamy Vivekananda College of Pharmacy, Elayampalayam, 637205, India.
Parasuraman PavadaiDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, M.S. Ramaiah University of Applied Sciences, M S R Nagar, Bengaluru, 560054, India.
Banoth Karan KumarMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani, 333031, India.
Sankaranarayanan MurugesanMedicinal Chemistry Research Laboratory, Department of Pharmacy, Birla Institute of Technology and Science-Pilani, Pilani, 333031, India.
Sachin ChandavarkarDepartment of Pharmacognosy, ASPM College of Pharmacy, Sangulwadi, 416 810, India. chandsachin@gmail.com.
Panneerselvam TheivendrenDepartment of Pharmaceutical Chemistry, Swamy Vivekanandha College of Pharmacy, Elayampalayam, 637205, India. tpsphc@gmail.com.
Kunjiappan SelvarajDepartment of Biotechnology, Kalasalingam Academy of Research and Education, Krishnankoil, 626126, India. selvapharmabio@gmail.com.ORCID http://orcid.org/0000-0002-6741-5118

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The most promising class of heterocyclic compounds in medicinal chemistry are those with the quinolin-2-one nucleus. It is a versatile heterocyclic molecule that has been put together with numerous pharmaceutical substances and is crucial in the creation of anticancer medications. In this view, the present research work deals with design, synthesis, and characterization of various analogous of quinolin-2-one nucleus and evaluation of their anticancer activity against MCF-7 cells (adenoma breast cancer cell line). Fourteen new compounds have been synthesised using suitable synthetic route and are characterized by FTIR,

Indexed as

Antineoplastic AgentsNeoplasmsQuinolinesCell ProliferationDrug Screening Assays, AntitumorErbB ReceptorsHumansModels, MolecularMolecular Docking SimulationMolecular StructureStructure-Activity RelationshipAntineoplastic AgentsErbB ReceptorsQuinolinesAnticancerBreast cancerDockingImatinibMolecular dynamicsQuinolin-2-one

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.